We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4661:TSEOriental Land Co., Ltd. Analysis

Data as of 2026-03-11 - not real-time

₩60,500.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

CLOBOT is trading at 60,500 KRW, comfortably above its 200‑day SMA (≈37,947 KRW) but below both the 20‑day (≈65,240 KRW) and 50‑day (≈65,970 KRW) averages, indicating a neutral price stance with a slight short‑term weakness. The RSI sits at 45, the MACD histogram is negative and the MACD signal is bearish, while volatility is extreme at over 112% for the past 30 days, suggesting sharp price swings ahead. Despite a hefty cash balance of ~47 billion KRW, the company posted a negative profit margin (‑5.2 %) and an EBITDA loss, with operating cash flow also in the red, leading to a sky‑high price‑to‑sales multiple of ~38. The market sentiment is in the “Extreme Greed” zone, yet the fundamentals are weak and the valuation appears stretched.
Given the increasing volume, the stock may attract speculative interest, but the combination of negative earnings, high valuation relative to sales, and a lack of dividend makes a sustainable upside uncertain. Investors should weigh the sizable cash reserve and potential growth in Korea’s robotics sector against the current profitability challenges before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below short‑term SMAs (20‑day and 50‑day)
  • bearish MACD histogram and signal
  • extreme 30‑day volatility

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • negative earnings and cash‑flow despite large cash pile
  • elevated price‑to‑sales multiple (~38)
  • uncertain path to profitability

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • substantial cash reserves to fund R&D and market expansion
  • growing demand for robotics integration in logistics and healthcare
  • need to achieve sustainable earnings to justify valuation

Key Metrics & Analysis

Financial Health

Revenue Growth100.00%
Profit Margin-5.21%
ROE-5.18%
Debt/Equity0.90
Op. Cash Flow₩-5186004480
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI45.0
Support₩50,100.00
Resistance₩74,500.00
MA 20₩65,240.00
MA 50₩65,970.00
MA 200₩37,947.15
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.51
Volatility112.57%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.